Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Abbott Laboratories today announced the successful completion of a multi-country diagnostic market development and professional training initiative across Latin America, delivering measurable ...

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish ...

Feb 4 (Reuters) - Medical device maker Abbott Laboratories has reported 860 serious injuries linked to the recall of some of ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Labs stock hit a 52-week low after an earnings miss, but CEO Robert Ford isn't flinching. Here is why his $2 million ...

Shares of Abbott Laboratories ABT advanced 1.60% to $110.83 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.97% to 6,932.30 ...

ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast higher full-year profits and steady sales growth.

The consensus rating for Abbott Laboratories is Outperform, based on 3 analyst ratings. With an average one-year price target ...